Abstract
While radiotherapy is proceeding, tumour cells may proliferate. The use of small individual doses reduces late morbidity. Continuous hyperfractionated accelerated radiation therapy (CHART), which reduces overall treatment from 6-7 weeks to 12 days and gives 36 small fractions, has now been tested in multicentre randomised controlled clinical trials. The trial in non-small-cell lung cancer included 563 patients and showed improvement in survival; 30% of the CHART patients were alive at 2 years compared with 20% in the control group (P = 0.006). In the 918 head and neck cases, there was only a small, non-significant improvement in the disease-free interval. In this interim analysis there was a trend for those with more advanced disease (T3 and T4) to show advantage; this will be subject to further analysis when the data are more mature. The early mucosal reactions appeared sooner and were more troublesome with CHART, however they quickly settled; so far no difference in long-term morbidity has emerged. These results support the hypothesis that tumour cell repopulation can occur during a conventional course of radiotherapy and be a cause of treatment failure.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
Saunders, M., Dische, S., Barrett, A. et al. Randomised multicentre trials of CHART vs conventional radiotherapy in head and neck and non-small-cell lung cancer: an interim report. CHART Steering Committee. Br J Cancer 73, 1455–1462 (1996). https://doi.org/10.1038/bjc.1996.276
Issue Date:
DOI: https://doi.org/10.1038/bjc.1996.276
This article is cited by
-
A Prospective Investigation of Swallowing, Nutrition, and Patient-rated Functional Impact Following Altered Fractionation Radiotherapy with Concomitant Boost for Oropharyngeal Cancer
Dysphagia (2012)
-
Linear quadratic and tumour control probability modelling in external beam radiotherapy
Journal of Mathematical Biology (2009)
-
Concurrent administration of Docetaxel and Stealth® liposomal doxorubicin with radiotherapy in non-small cell lung cancer : excellent tolerance using subcutaneous amifostine for cytoprotection
British Journal of Cancer (2002)
-
Cisplatin-based chemotherapy and hyperfractionated radiotherapy for stage III non-small cell lung cancer: survival and patterns of failure after long follow-up
Revista de Oncología (2002)
-
Recent progress in optimizing radiotherapy in chemo-radiotherapy for stage III non-small cell lung cancer
Revista de Oncología (2002)